Mandate

Vinge has advised Corline Biomedical AB (publ) in connection with a directed share issue

The share issue was directed to a number of Swedish and international institutional investors on the basis of an accelerated bookbuilding process.

Corline intends to use the issue proceeds to continue the development of Renaparin® in phase 2 clinical development to interim data, build the organisation to increase proceeds to the medical technology branch, improve the financial flexibility and strengthen the working capital.

Vinge’s team has consisted of Dain Hård Nevonen, Amanda Knutsson and Clara Sohlberg.

Related

Vinge advises on the sale of RK Projektledning to Qflow

Vinge has advised the sellers in connection with the sale of all shares in RK Projektledning AB to Qflow Group.
December 05, 2025

Vinge represents IKEA Forestry Investment AB in connection with the acquisition of forest land in Latvia and Lithuania

Vinge assists IKEA Forestry Investment AB (a company within the Inter IKEA group) in the acquisition of a Latvian and a Lithuanian company from Dasos Timberland Fund II (a fund managed by CapMan Natural Capital).
December 05, 2025

Vinge advises and Valcon in connection with the acquisition of Bricobomba

Bricobomba AB is a Swedish company with expertise in data and AI. The acquisition will strengthen Valcon’s capacity in the Nordic region and further expand the company’s ability to deliver comprehensive data and AI-based services to its customers on a pan-European scale.
December 05, 2025